Abstracts tagged "Outcome measures"

Abstract Number: 0569 • ACR Convergence 2025
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Floris A. van Gaalen¹, Victoria Navarro-Compan², Xenofon Baraliakos³, Filip Van den Bosch⁴, Lianne S. Gensler⁵, Ihsane Hmamouchi⁶, Robert Landewé⁷, Pedro Machado⁸, Helena Marzo-Ortega⁹, Valeria Rios Rodriguez¹⁰, Denis Poddubnyy¹¹, Sofia Ramiro¹² and Désirée Van Der Heijde¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ⁷Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁹NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹⁰Charité-Universitétsmedizin Berlin, corporate member of Freie universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ¹¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…
Abstract Number: 0441 • ACR Convergence 2025
Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA
Charis Meng¹, Caci Julia², Kelsey Gripp², Deanna Jannat-Khah¹, Yvonne Lee³, Susan J. Bartlett⁴, Clifton Bingham⁵ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Northwestern University, Chicago, IL, ⁴McGill University, Beaconsfield, QC, Canada, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: RA disease worsening contributes to joint damage and cardiovascular disease. While measures of improvement are established in RA, we do not have uniform definitions…
Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Juan Schmukler¹, Tengfei Li² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
Abstract Number: 2545 • ACR Convergence 2025
Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Valeria Manfrè¹, elena treppo², Maria Pillon³, Maria De Martino⁴, Cinzia Fabro⁵, Miriam Isola⁴, Martina Fabris⁶, Francesco Curcio⁶ and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, Udine, Italy, ⁴Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁶Institute of Clinical Pathology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy
Background/Purpose: Cryoglobulinemic vasculitis (CryoVas) is a rare immune-complex-mediated disorder, often associated with hepatitis C virus (HCV) infection, autoimmune diseases (ADs), or other etiologies. Despite its…
Abstract Number: 2334 • ACR Convergence 2025
Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
Dafne capelusnik¹, Philip Gardiner², Elena Nikiphorou³, Désirée Van Der Heijde⁴, Robert Landewé⁵, Astrid Van Tubergen⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³King’s College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁶Maastricht university, Maastricht, Netherlands, ⁷Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study, a study on spinal mobility measures in healthy individuals, showed that the Bath Ankylosing Spondylitis Metrology Index (BASMI) often overestimates spinal…
Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Philip Conaghan¹, nathaniel katz², Asger Bihlet³, Laus W Wullum⁴, Kerry af Forselles⁵, C Michael Perkins⁵, Bernadette Hughes⁶, Claire Herholdt⁷ and Iwona Bombelka⁸, ¹University of Leeds, Leeds, United Kingdom, ²Rin Sof Innovation, Ltd, Boston, MA, ³NBCD A/S, Herlev, Denmark, ⁴Omicron A/S, Copenhagen, Denmark, ⁵Levicept, Sandwich, United Kingdom, ⁶Levicept, Ashtead, United Kingdom, ⁷Levicept Ltd, Ashtead, United Kingdom, ⁸Levicept, Sandwich, Kent, United Kingdom
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…
Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Fabian Rodriguez Quinonez⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…
Abstract Number: 0874 • ACR Convergence 2025
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Atul Deodhar¹, Ricardo Blanco², Arthur Kavanaugh³, Alice Gottlieb⁴, Laura Coates⁵, Christopher Ritchlin⁶, Alan Kivitz⁷, Xiaofeng Zeng⁸, Akimichi Morita⁹, Diamant Thaçi¹⁰, Stefan Varga¹¹, Kexuan Li¹¹, Ying-Ming Jou¹², Eleni Vritzali¹³ and Philip J. Mease¹⁴, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³University of California, San Diego, School of Medicine, San Diego, CA, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁹Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol Myers Squibb, Boudry, Switzerland, ¹⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over…
Abstract Number: 0440 • ACR Convergence 2025
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
Charis Meng¹, Jing Song², Lutfiyya muhammad³, Caci Julia⁴, Tuhina Neogi⁵, Marcy Bolster⁶, Wendy Marder⁷, Clifton Bingham⁸ and Yvonne Lee⁹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Hospital for Special Surgery, New York, ⁵Boston University School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Concord, MA, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins University, Baltimore, MD, ⁹Northwestern University, Chicago, IL
Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
Abstract Number: 0217 • ACR Convergence 2025
Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
Catherine Nasrallah¹, Christine Hariz², Shanthini Kasturi³, Wambui Machua⁴, Jinoos Yazdany⁵, Christie Bartels⁶, Kate Chiseri⁷, Starla Blanks⁷, Patti Katz⁸, Cherish Wilson⁹, April Jorge¹⁰, Beth Radtke¹¹, Tom Tack⁷ and Shivani Garg¹², ¹University of California San Francisco (UCSF), San Francisco, CA, ²University of California San Francisco (UCSF, San Francisco, CA, ³Tufts Medical Center, Boston, MA, ⁴Piedmont Healthcare, Atlanta, GA, ⁵UCSF, San Francisco, CA, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷American College of Rheumatology, Atlanta, GA, ⁸UCSF, San Rafael, CA, ⁹UCSF / SFVA, San Francisco, CA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹ACR, Atlanta, GA, ¹²University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease that presents unique care challenges. To improve high-quality patient-centered care, the American College of Rheumatology (ACR),…
Abstract Number: 2538 • ACR Convergence 2025
Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease
Rafael Gálvez Sánchez¹, José Luis Martín-Varillas², Lara Sánchez Bilbao³, Ivan Ferraz Amaro⁴, Carmen Lasa Teja⁵, Elena Aurrecoechea⁶, Diana Prieto-Peña⁷ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ⁶Hospital Sierrallana, CANTABRIA, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain
Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision…
Abstract Number: 2333 • ACR Convergence 2025
Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
Dafne capelusnik¹, Philip Gardiner², Annelies Boonen³, Elena Nikiphorou⁴ and Sofia Ramiro⁵, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁴King’s College London, London, United Kingdom, ⁵Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study showed that BASMI often misclassifies spinal mobility, especially in older and taller individuals. To address this, the Corrected AxSpA Metrology Index…
Abstract Number: 2086 • ACR Convergence 2025
WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials
Dawn McGuire¹, Alan Brett², Neil Segal³, Meghan Miller⁴, David Rosen¹ and Yoshi Kumagai⁵, ¹OrthoTrophix, Inc, Foster City, CA, ²Imorphics, Manchester M²⁰ ²HJ, England, United Kingdom, ³KUMC, Kansa City, KS, ⁴OrthoTrophics, Foster City, CA, ⁵OrthoTrophix, Foster City, CA
Background/Purpose: TPX-100, a peptide derived from matrix extracellular phosphoglycoprotein (MEPE), is in development as a potential disease-modifying osteoarthritis drug (DMOAD) for mild to severe knee…

« Previous Page
1
…
7
8
9
10
11
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].